Statins May Reduce Risk for Hepatocellular Carcinoma in Chronic Liver Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 19, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, March 19, 2025 -- For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published online March 17 in JAMA Internal Medicine.

Jonggi Choi, M.D., Ph.D., from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues used data from the Research Patient Data Registry from 2000 to 2023 for patients aged 40 years or older with chronic liver disease and a baseline Fibrosis-4 (FIB-4) score of 1.3 or higher to examine the association between statin use and the risk for HCC and hepatic decompensation.

The analysis included 16,501 participants: 3,610 statin users and 12,891 nonusers. The researchers found that compared with nonusers, statin users had a significantly lower 10-year cumulative incidence of HCC (3.8 versus 8.0 percent) and hepatic decompensation (10.6 versus 19.5 percent). The adjusted subhazard ratios were 0.67 and 0.78 for HCC and hepatic decompensation, respectively. Further reductions in HCC and hepatic decompensation risks were seen in association with exposure to lipophilic statins and duration of statin use (≥600 cumulative defined daily dose). Among 7,038 patients with serial FIB-4 data with intermediate baseline FIB-4 scores, 14.7 percent of statin users and 20.0 percent of nonusers transitioned to the high group. For patients with high baseline FIB-4 scores, 31.8 and 7.0 percent of statin users transitioned to the intermediate-risk and low-risk groups, respectively, compared with 18.8 and 4.3 percent of nonusers.

"These findings underscore the potential of statins as chemopreventive agents against HCC through their role in mitigating fibrosis progression," the authors write.

One author disclosed ties to Gilead Sciences Research.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-20 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords